NCT00421031View on ClinicalTrials.gov

Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause

PHASE3CompletedINTERVENTIONAL

Enrollment

540

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

April 30, 2004

Conditions

Vasomotor Symptoms

Interventions

DRUG

DVS-233 SR

Trial Locations (41)

15090

Wexford

16502

Erie

19713

Newark

23507

Norfolk

27103

Winston-Salem

29605

Greenville

30342

Atlanta

31405

Savannah

32701

New Port Richey

32763

Orange City

33143

Miami

33160

Aventura

33409

West Palm Beach

33709

Tampa

33781

Pinellas Park

33990

Fort Myers

34285

West Venice

34452

Inverness

34470

Ocala

36116

Montgomery

39216

Jackson

40536

Lexington

44406

Canton

45249

Cincinnati

45267

Cincinnati

47630

Newburgh

55387

Chaska

59101

Billings

63131

St Louis

71103

Shreveport

78229

San Antonio

80907

Colorado Springs

85345

Peoria

87102

Albuquerque

87131

Albuquerque

89119

Las Vegas

89509

Reno

92123

San Diego

94143

Stanford

97201

Portland

04102

Portland

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00421031 - Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause | Biotech Hunter | Biotech Hunter